老年慢性冠状动脉综合征患者调节性T细胞与血清脂蛋白（a）的相关性研究

吕彩霞; 高丽霞; 王素星; 邵伟华; 姚丽霞; 苑晓烨; 赵景茹; 张明明; 杨爽; 李绍冰

doi:10.13201/j.issn.1001-1439.2021.10.008

老年慢性冠状动脉综合征患者调节性T细胞与血清脂蛋白（a）的相关性研究

- 1. 河北省人民医院老年病科(石家庄,052260);
- 2. 河北省人民医院神经内科;
- 3. 河北省人民医院检验科
基金项目:
国家自然科学基金青年科学基金(No:82001229)

河北省自然科学基金青年科学基金(No:H2016307015)

河北省医学科学研究重点课题计划(No:20180003、20160485)

河北省科技支撑项目(No:20377776D)

详细信息

通讯作者: 李绍冰,E-mail:lishaobing802@sina.com

中图分类号: R541.4

收稿日期: 2021-03-10

修回日期: 2021-04-07

Relationship between regulatory T cells and serum lipoprotein（a） in elderly patients with chronic coronary syndrome

- 1. Department of Geriatrics,Hebei General Hospital, Shijiazhuang, 052260, China;
- 2. Department of Neurology,Hebei General Hospital;
- 3. Clinical Laboratory,Hebei General Hospital

More Information

Corresponding author: LI Shaobing, E-mail: lishaobing802@sina.com

Received Date: 10 March 2021

Revised Date: 07 April 2021

摘要

摘要: 目的:探讨老年慢性冠状动脉综合征患者调节性T细胞水平与血清脂蛋白a[Lp(a)]的相关性。方法:入选年龄≥65岁的慢性冠状动脉综合征患者,且低密度脂蛋白胆固醇(LDL-C)水平已达治疗目标值;根据Lp(a)水平筛选血清Lp(a)正常组(0~300 mg/L)及血清Lp(a)升高组(>300 mg/L);检测两组患者外周血中调节性T细胞及炎性标志物的水平,并进行差异性及相关性分析。结果:血清Lp(a)升高组外周血调节性T细胞及抗炎细胞因子的表达明显降低,致炎细胞因子明显升高(均P<0.05);血清Lp(a)与调节性T细胞的表达、炎性标志物明显相关。结论:血清Lp(a)可能通过调控调节性T细胞的表达参与老年慢性冠状动脉综合征患者的免疫炎症失衡。
- 慢性冠状动脉综合征 /
- 调节性T细胞 /
- 脂蛋白(a) /
- 炎症
Abstract: Objective: To investigate the correlation between the expression of regulatory T cells and serum lipoprotein(a) in elderly patients with the chronic coronary syndrome.Methods: Patients aged ≥ 65 years with chronic coronary syndrome were enrolled, and the level of low-density lipoprotein cholesterol(LDL-C) reached the therapeutic target. According to the level of lipoprotein(a), all patients were divided into two groups: the normal serum lipoprotein(a) group(0-300 mg/L) and the elevated serum lipoprotein(a) group(>300 mg/L). The levels of regulatory T cells and inflammatory markers in peripheral blood were detected, and the differences and correlations were analyzed.Results: The expression of regulatory T cells and anti-inflammatory cytokines in peripheral blood were significantly decreased. In contrast, the inflammatory cytokines were significantly increased in the elevated serum lipoprotein(a) group(P<0.05). The serum lipoprotein(a) was significantly correlated with regulatory T cells and inflammatory markers.Conclusion: Serum lipoprotein(a) may be involved in immuno-inflammatory imbalance by regulating the expression of regulatory T cells in elderly patients with chronic coronary syndromes.
- chronic coronary syndrome /
- regulatory T cells /
- lipoprotein(a) /
- inflammation

HTML全文

参考文献(20)

[1]	Knuuti J,Wijns W,Saraste A,et al.2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes[J].Eur Heart J,2020,41:407-477.
[2]	Authors/Task Force Members:,Catapano AL,Graham I,et al.2016 ESC/EAS Guidelines for the Management of Dyslipidaemias:The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology(ESC)and European Atherosclerosis Society(EAS)Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation(EACPR)[J].Atherosclerosis,2016,253:281-344.
[3]	Khera AV,Everett BM,Caulfield MP,et al.Lipoprotein(a)concentrations,rosuvastatin therapy,and residual vascular risk:an analysis from the JUPITER Trial(Justification for the Use of Statins in Prevention:an Intervention Trial Evaluating Rosuvastatin)[J].Circulation,2014,129(6):635-642.
[4]	Verbeek R,Hoogeveen RM,Langsted A,et al.Cardiovascular disease risk associated with elevated lipoprotein(a)attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting[J].Eur Heart J,2018,39(27):2589-2596.
[5]	Tsimikas S.A test in context:Lipoprotein(a):diagnosis,prognosis,controversies,and emerging therapies[J].J Am Coll Cardiol,2017,69(6):692-711.
[6]	Schmidt K,Noureen A,Kronenberg F,et al.Structure,function,and genetics of lipoprotein(a)[J].J Lipid Res,2016,57(8):1339-1359.
[7]	Stiekema L,Stroes E,Verweij SL,et al.Persistent arterial wall inflammation in patients with elevated lipoprotein(a)despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment[J].Eur Heart J,2019,40(33):2775-2781.
[8]	Wolf D,Gerhardt T,Winkels H,et al.Pathogenic autoimmunity in atherosclerosis evolves from initially protective apolipoprotein B100-reactive CD4+ T-regulatory cells[J].Circulation,2020,142(13):1279-1293.
[9]	诸骏仁,高润霖,赵水平,等.中国成人血脂异常防治指南(2016年修订版)[J].中华心血管病杂志,2016,44(10):833-853.
[10]	Nestel PJ,Barnes EH,Tonkin AM,et al.Plasma lipoprotein(a)concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease[J].Arterioscler Thromb Vasc Biol,2013,33(12):2902-2908.
[11]	苏冠华,程翔.调脂药物的抗炎作用及相关研究进展[J].中国医学前沿杂志(电子版),2019,11(5):1-5.
[12]	Jang AY,Han SH,Sohn IS,et al.Lipoprotein(a)and cardiovascular diseases-revisited[J].Circ J,2020,84(6):867-874.
[13]	Orho-Melander M.Genetics of coronary heart disease:towards causal mechanisms,novel drug targets and more personalized prevention[J].J Intern Med,2015,278(5):433-446.
[14]	van der Valk FM,Bekkering S,Kroon J,et al.Oxidized phospholipids on lipoprotein(a)elicit arterial wall inflammation and an inflammatory monocyte response in humans[J].Circulation,2016,134(8):611-624.
[15]	Sharma M,Schlegel MP,Afonso MS,et al.Regulatory T cells license macrophage pro-resolving functions during atherosclerosis regression[J].Circ Res,2020,127(3):335-353.
[16]	胡继军,王梅,方静,等.葡萄糖调节蛋白78对单核巨噬细胞分化的影响[J].临床血液学杂志,2019,32(4):252-257.
[17]	Mobarek D,Karasik PA,Tomer M,et al.High Lp(a)associated with very premature coronary heart disease[J].J Clin Lipidol,2019,13(3):402-404.
[18]	Yousuf O,Mohanty BD,Martin SS,et al.High-sensitivity C-reactive protein and cardiovascular disease:a resolute belief or an elusive link?[J].J Am Coll Cardiol,2013,62(5):397-408.
[19]	Moriya J.Critical roles of inflammation in atherosclerosis[J].J Cardiol,2019,73(1):22-27.
[20]	鲍微,徐燕.血清总胆红素、C反应蛋白及脂蛋白a与高脂血症患者的关系研究[J].临床血液学杂志,2020,33(6):422-424.